Lytenava FDA Approval Status
FDA Approved: No
Brand name: Lytenava
Generic name: bevacizumab-vikg
Dosage form: Intravitreal Injection
Company: Outlook Therapeutics
Lytenava (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab in development for the treatment of wet AMD and other retinal diseases.
Development timeline for Lytenava
| Date | Article |
|---|---|
| Mar 31, 2022 | Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
